Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Sanara MedTech (SMTI) Cost of Revenue (2016 - 2025)

Sanara MedTech (SMTI) has disclosed Cost of Revenue for 15 consecutive years, with $1.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cost of Revenue fell 5.91% year-over-year to $1.9 million, compared with a TTM value of $7.9 million through Sep 2025, up 2.82%, and an annual FY2024 reading of $8.1 million, up 3.66% over the prior year.
  • Cost of Revenue was $1.9 million for Q3 2025 at Sanara MedTech, down from $1.9 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $2.4 million in Q4 2022 and bottomed at $474433.0 in Q1 2021.
  • Average Cost of Revenue over 5 years is $1.6 million, with a median of $1.9 million recorded in 2025.
  • The sharpest move saw Cost of Revenue skyrocketed 330.55% in 2022, then fell 24.52% in 2023.
  • Year by year, Cost of Revenue stood at $782772.0 in 2021, then soared by 202.66% to $2.4 million in 2022, then dropped by 24.52% to $1.8 million in 2023, then rose by 25.78% to $2.2 million in 2024, then fell by 16.67% to $1.9 million in 2025.
  • Business Quant data shows Cost of Revenue for SMTI at $1.9 million in Q3 2025, $1.9 million in Q2 2025, and $1.8 million in Q1 2025.